Trial Profile
Multicenter Double-blind Randomized Parallel Comparative Study of Efficacy and Safety of BCD-066 (CJSC BIOCAD, Russia) and Aranesp (Amgen Europe B.V., Netherlands) in Treatment of Anemia in Chronic Kidney Disease Patients on Dialysis
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Darbepoetin alfa (Primary)
- Indications Anaemia
- Focus Therapeutic Use
- Sponsors Biocad
- 29 May 2019 Status changed from recruiting to completed.
- 01 Sep 2016 Planned End Date changed from 1 Mar 2017 to 1 Sep 2017.
- 01 Sep 2016 Planned primary completion date changed from 1 Feb 2017 to 1 Mar 2017.